Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$41.18 USD
+1.63 (4.12%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $41.19 +0.01 (0.02%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
XENE 41.18 +1.63(4.12%)
Will XENE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for XENE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XENE
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
XENE: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now
Other News for XENE
Analysts Are Bullish on These Healthcare Stocks: Xenon (XENE), Evolent Health (EVH)
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Xenon Pharmaceuticals Showcases Progress at Global Conference
Xenon’s Depression Drug Shows Early Promise
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting